FDA grants Breakthrough Therapy designation for B7-H3 CAR T-cell therapy for diffuse intrinsic pontine glioma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BrainChild Bio Inc. announced that its investigational B7-H3 targeting autologous CAR T-cell therapy has been granted Breakthrough Therapy designation by FDA for the treatment of diffuse intrinsic pontine glioma, an incurable pediatric brain tumor. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login